Phenomics Australia led discussions towards a proposal for an AI-Enhanced Drug Discovery (AIEDD) Cooperative Research Centre (AIEDD CRC), held on 16 October at the University of Sydney.
The event brought together key stakeholders from research, industry, and government to explore how artificial intelligence is transforming drug discovery, from enabling infrastructure and next-generation omics to regulatory frameworks and commercialisation.
The full-day AIEDD CRC Symposium featured insightful keynotes, expert panel discussions, and interactive roundtables examining the future of AI-enabled drug discovery in Australia. Topics included the application of AI in drug development, the integration of omics technologies, and the infrastructure driving innovation across the sector.
Phenomics Australia CEO, Professor Michael Dobbie, contributed to a panel discussion on Innovation, Enabling Infrastructure, Technologies, and Emerging R&D in Drug Discovery, highlighting our ongoing commitment to supporting cutting-edge research and collaboration across the national biomedical landscape.
The symposium provided an timely opportunity for participants to connect and exchange ideas with peers, industry leaders, and policymakers shaping the future of AI-driven biomedical research in Australia.
Learn more about the initiative at: https://www.aieddcrc.com/
